Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

PMID:
19339269
[PubMed - indexed for MEDLINE]
Free Article
2.

Abiraterone acetate for the treatment of prostate cancer.

Ryan CJ, Cheng ML.

Expert Opin Pharmacother. 2013 Jan;14(1):91-6. doi: 10.1517/14656566.2013.745852. Epub 2012 Nov 30. Review.

PMID:
23199349
[PubMed - indexed for MEDLINE]
3.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
[PubMed - indexed for MEDLINE]
4.

Emerging biological observations in prostate cancer.

Shah S, Small E.

Expert Rev Anticancer Ther. 2010 Jan;10(1):89-101. doi: 10.1586/era.09.161. Review.

PMID:
20014889
[PubMed - indexed for MEDLINE]
5.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS.

Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Review.

PMID:
19223900
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.

Nandha R.

J Postgrad Med. 2012 Jul-Sep;58(3):203-6. Review.

PMID:
23023354
[PubMed - indexed for MEDLINE]
Free Article
7.

The androgen/androgen receptor axis in prostate cancer.

Bluemn EG, Nelson PS.

Curr Opin Oncol. 2012 May;24(3):251-7. doi: 10.1097/CCO.0b013e32835105b3. Review.

PMID:
22327838
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

ETS gene fusions in prostate cancer.

Clark JP, Cooper CS.

Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Review.

PMID:
19657377
[PubMed - indexed for MEDLINE]
9.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

PMID:
19509232
[PubMed - indexed for MEDLINE]
Free Article
10.

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

White NM, Feng FY, Maher CA.

Curr Drug Targets. 2013 Apr;14(4):450-9. Review.

PMID:
23410129
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

CYP17 inhibition as a hormonal strategy for prostate cancer.

Reid AH, Attard G, Barrie E, de Bono JS.

Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237. Review.

PMID:
18985049
[PubMed - indexed for MEDLINE]
12.

Prostate cancer stem cells.

Tu SM, Lin SH.

Clin Genitourin Cancer. 2012 Jun;10(2):69-76. doi: 10.1016/j.clgc.2012.01.002. Epub 2012 Mar 14. Review.

PMID:
22421313
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Advancing precision medicine for prostate cancer through genomics.

Roychowdhury S, Chinnaiyan AM.

J Clin Oncol. 2013 May 20;31(15):1866-73. doi: 10.1200/JCO.2012.45.3662. Epub 2013 Apr 15. Review.

PMID:
23589550
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Interrogating genomic and epigenomic data to understand prostate cancer.

Kim J, Yu J.

Biochim Biophys Acta. 2012 Apr;1825(2):186-96. doi: 10.1016/j.bbcan.2011.12.003. Epub 2012 Jan 3. Review.

PMID:
22240201
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Genomic Rearrangements of PTEN in Prostate Cancer.

Phin S, Moore MW, Cotter PD.

Front Oncol. 2013 Sep 17;3:240. doi: 10.3389/fonc.2013.00240. Review.

PMID:
24062990
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk